The CHMP opinion from 15 October now goes to the European Commission. In trials, people on the daily orforglipron tablet lost about 5% to 11% of body weight over 72 weeks.
Recap by typeshit. Full story at London Daily News.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
The telehealth company is also adding blood testing services alongside the lower costs for its compounded GLP-1 options.
The Pennsylvania county is funding a study into whether the GLP-1 drug can help people with substance use disorders.
Amy Maxmen reports on how experimental peptides are being hyped in optimization circles and where the talk goes wrong.
Loading…